Clinical outcomes of peripheral blood stem cell transplantation for aggressive peripheral T-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2018.09.005
- Author:
Wen Rong HUANG
1
;
Zhen Yang GU
;
Hong Hua LI
;
Jian BO
;
Shu Hong WANG
;
Fei LI
;
Xiao Ning GAO
;
Li Ping DOU
;
Yu ZHAO
;
Yu JING
;
Hai Yan ZHU
;
Quan Shun WANG
;
Li YU
;
Chun Ji GAO
;
Dai Hong LIU
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Lymphoma, T-cell, peripheral;
Survival analysis
- MeSH:
Adolescent;
Adult;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, T-Cell, Peripheral/therapy*;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Peripheral Blood Stem Cell Transplantation;
Retrospective Studies;
Transplantation, Autologous;
Transplantation, Homologous;
Treatment Outcome;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(9):729-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate clinical outcomes of autologous and allogeneic peripheral blood stem cell transplantation (PBSCT) for aggressive peripheral T-cell lymphoma (PTCL). Methods: From June 2007 to June 2017, clinical data of PTCL patients who underwent PBSCT were assessed retrospectively. Results: Among 41 patients, 30 was male, 11 female, and median age was 38(13-57) years old. Seventeen patients with autologous PBSCT (auto-PBSCT) and 24 patients with allogeneic PBSCT (allo-PBSCT) were enrolled in this study. Eight patients (8/17, 47.1%) in auto-PBSCT group were ALK positive anaplastic large cell lymphoma (ALCL), 7 patients (7/24, 29.2%) with NK/T cell lymphoma and 9 patients (9/24, 37.5%) with PTCL-unspecified (PTCL-U) in allo-PBSCT group (P=0.035). There were 58.8% patients (10/17) in complete response (CR) status and 11.8% (2/17) in progression disease (PD) status before transplantation in auto-PBSCT group, and 8.3% (2/24) in CR status and 45.8% (11/24) in PD status before transplantation in allo-PBSCT group (P=0.026). The 2-years cumulative overall survival (OS) were (64.0±10.8)% and (53.5±9.7)% for auto-PBSCT and allo-PBSCT respectively (P=0.543). The 2-years cumulative disease-free survival (DFS) were (57.1±12.4)% and (53.5±10.6)% for auto-PBSCT and allo-PBSCT respectively (P=0.701). In patients with dead outcomes after PBSCT, 83.3% (5/6) of death cause was relapse in auto-PBSCT and 41.7% (5/12) of death cause was relapse in allo-PBSCT. Conclusion: Both auto-PBSCT and allo-PBSCT were effective for PTCL. Allo-PBSCT maybe was better than auto-PBSCT for high-risk PTCL with poor prognosis.
